Medtronic Defends Endeavor DES Late Loss, Questions Clinical Relevance
This article was originally published in The Gray Sheet
Executive Summary
The relatively high rates of late lumen loss in Medtronic's ENDEAVOR-I drug-eluting stent trial can be traced to the large reference vessel size of the study subjects, according to Harvard Medical School's Richard Kuntz, MD
You may also be interested in...
Guidant Champion Stent Design Flaw Delays Marketing By Up To Eight Months
A European launch of Guidant's Champion everolimus drug-eluting stent will require no additional clinical data, despite needed design and manufacturing changes, the firm says
Guidant Champion Stent Design Flaw Delays Marketing By Up To Eight Months
A European launch of Guidant's Champion everolimus drug-eluting stent will require no additional clinical data, despite needed design and manufacturing changes, the firm says
FDA Reviews Drug-Eluting Stent Late Loss: More Than A Marketing Concept?
Late lumen loss should be regarded strictly in the context of drug-eluting stent safety, because its value as a surrogate measure of efficacy remains unclear, FDA cautions